Key clinical point: Bisphosphonates and denosumab are effective for preventing osteoporosis in men with prostate cancer being treated with androgen deprivation therapy, selective estrogen receptor modulators are a less effective alternative, and exercise is insufficient in isolation, but has a role as an adjunct for care.
Major finding: Bisphosphonates led to a significant improvement in lumbar BMD (mean difference, 7.09%; 95% CI, 5.05%-9.13%; P < .00001); femoral neck (4.63%; 95% CI, 0.87%-8.4%; P = .02); total hip (3.16%; 95% CI, 0.09%-6.23%; P = .04).
Study details: A meta-analysis of data from 25 studies on men who received an intervention to prevent osteoporosis after a diagnosis of prostate cancer and treatment with ADT.
Disclosures: The authors said they had no financial disclosures or conflicts of interest to report.
Eur Urol Oncol. 2019;2(5):551-61.